S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
It's almost April 15. Here's how to reduce stress and get your taxes done
Nearing 50 Supreme Court arguments in, lawyer Lisa Blatt keeps winning
Can homeless people be fined for sleeping outside? A rural Oregon city asks the US Supreme Court
The craze for Masters gnomes is growing. Little golf-centric statue is now a coveted collector item
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
It's almost April 15. Here's how to reduce stress and get your taxes done
Nearing 50 Supreme Court arguments in, lawyer Lisa Blatt keeps winning
Can homeless people be fined for sleeping outside? A rural Oregon city asks the US Supreme Court
The craze for Masters gnomes is growing. Little golf-centric statue is now a coveted collector item
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
It's almost April 15. Here's how to reduce stress and get your taxes done
Nearing 50 Supreme Court arguments in, lawyer Lisa Blatt keeps winning
Can homeless people be fined for sleeping outside? A rural Oregon city asks the US Supreme Court
The craze for Masters gnomes is growing. Little golf-centric statue is now a coveted collector item
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
It's almost April 15. Here's how to reduce stress and get your taxes done
Nearing 50 Supreme Court arguments in, lawyer Lisa Blatt keeps winning
Can homeless people be fined for sleeping outside? A rural Oregon city asks the US Supreme Court
The craze for Masters gnomes is growing. Little golf-centric statue is now a coveted collector item

Axsome Therapeutics (AXSM) Stock Price, News & Analysis

$69.15
-2.58 (-3.60%)
(As of 04/12/2024 ET)
Today's Range
$68.28
$72.28
50-Day Range
$69.15
$97.64
52-Week Range
$55.02
$98.40
Volume
594,653 shs
Average Volume
671,203 shs
Market Capitalization
$3.28 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$119.67

Axsome Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.92 Rating Score
Upside/​Downside
73.1% Upside
$119.67 Price Target
Short Interest
Bearish
16.15% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.03
Upright™ Environmental Score
News Sentiment
-0.08mentions of Axsome Therapeutics in the last 14 days
Based on 15 Articles This Week
Insider Trading
Selling Shares
$3.99 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($3.73) to $0.70 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.37 out of 5 stars

Medical Sector

98th out of 923 stocks

Pharmaceutical Preparations Industry

30th out of 428 stocks

AXSM stock logo

About Axsome Therapeutics Stock (NASDAQ:AXSM)

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

AXSM Stock Price History

AXSM Stock News Headlines

Options trading has suddenly become more reliable.
When it hits at a stunning 96% win rate... Options trading has suddenly become more reliable.
Options trading has suddenly become more reliable.
When it hits at a stunning 96% win rate... Options trading has suddenly become more reliable.
See More Headlines
Receive AXSM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Axsome Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/20/2024
Today
4/13/2024
Next Earnings (Confirmed)
5/06/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:AXSM
Employees
545
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$119.67
High Stock Price Target
$190.00
Low Stock Price Target
$81.00
Potential Upside/Downside
+73.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.92
Research Coverage
12 Analysts

Profitability

Net Income
$-239,240,000.00
Pretax Margin
-88.06%

Debt

Sales & Book Value

Annual Sales
$270.60 million
Book Value
$4.04 per share

Miscellaneous

Free Float
35,767,000
Market Cap
$3.28 billion
Optionable
Optionable
Beta
1.13
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Dr. Herriot Tabuteau M.D. (Age 56)
    Founder, Chairman, CEO & President
    Comp: $1.32M
  • Mr. Nick Pizzie CPAMr. Nick Pizzie CPA (Age 49)
    M.B.A., Chief Financial Officer
    Comp: $732.94k
  • Mr. Mark L. Jacobson (Age 41)
    COO & Secretary
    Comp: $784.66k
  • Mr. Hunter Murdock Esq. (Age 44)
    General Counsel & Secretary
    Comp: $735.39k
  • Dr. Amanda Jones Pharm.D. (Age 41)
    Senior Vice President of Clinical Development
  • Ms. Lori Englebert M.B.A. (Age 46)
    Executive Vice President of Commercial & Business Development
  • Joseph Debrah-Afful CPA
    M.B.A., Director of Finance

AXSM Stock Analysis - Frequently Asked Questions

Should I buy or sell Axsome Therapeutics stock right now?

12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Axsome Therapeutics in the last year. There are currently 1 hold rating and 11 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" AXSM shares.
View AXSM analyst ratings
or view top-rated stocks.

What is Axsome Therapeutics' stock price target for 2024?

12 equities research analysts have issued 1 year target prices for Axsome Therapeutics' stock. Their AXSM share price targets range from $81.00 to $190.00. On average, they predict the company's share price to reach $119.67 in the next twelve months. This suggests a possible upside of 73.1% from the stock's current price.
View analysts price targets for AXSM
or view top-rated stocks among Wall Street analysts.

How have AXSM shares performed in 2024?

Axsome Therapeutics' stock was trading at $79.59 at the start of the year. Since then, AXSM shares have decreased by 13.1% and is now trading at $69.15.
View the best growth stocks for 2024 here
.

When is Axsome Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 6th 2024.
View our AXSM earnings forecast
.

How can I listen to Axsome Therapeutics' earnings call?

Axsome Therapeutics will be holding an earnings conference call on Monday, May 6th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Axsome Therapeutics' earnings last quarter?

Axsome Therapeutics, Inc. (NASDAQ:AXSM) issued its quarterly earnings results on Tuesday, February, 20th. The company reported ($0.73) EPS for the quarter, beating analysts' consensus estimates of ($1.21) by $0.48. The business earned $71.53 million during the quarter, compared to the consensus estimate of $70.38 million. Axsome Therapeutics had a negative trailing twelve-month return on equity of 70.67% and a negative net margin of 88.41%.

What other stocks do shareholders of Axsome Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Axsome Therapeutics investors own include Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Dicerna Pharmaceuticals (DRNA), Amarin (AMRN), Sarepta Therapeutics (SRPT), Micron Technology (MU), Pfizer (PFE), AbbVie (ABBV), Alibaba Group (BABA) and Bristol-Myers Squibb (BMY).

When did Axsome Therapeutics IPO?

Axsome Therapeutics (AXSM) raised $52 million in an initial public offering on Thursday, November 19th 2015. The company issued 4,300,000 shares at a price of $11.00-$13.00 per share. Ladenburg Thalmann and Cantor Fitzgerald & Co. served as the underwriters for the IPO and Brean Capital was co-manager.

Who are Axsome Therapeutics' major shareholders?

Axsome Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Yarbrough Capital LLC (0.01%). Insiders that own company stock include Mark Coleman, Mark E Saad, Mark L Jacobson, Nick Pizzie and Roger Jeffs.
View institutional ownership trends
.

How do I buy shares of Axsome Therapeutics?

Shares of AXSM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:AXSM) was last updated on 4/13/2024 by MarketBeat.com Staff

From Our Partners